From Raw Data to Strategic Insight: Turning AI into a Competitive Advantage at Merck

Merck, a global German pharmaceutical company, conducts cutting-edge research to develop new treatments for chronic and often incurable diseases. Its scientific teams rely on vast and complex data sets to understand the real-world impact of these treatments on patients and to improve clinical decision-making.

In this context, Thiga supported Merck in structuring its product governance, stabilizing its generative AI solution, and scaling an analytics platform designed to transform patient and caregiver insights into a true strategic asset.

• Managing data complexity at scale: unify and validate multiple heterogeneous sources, from physicians and scientific literature to social media, while integrating LLM models with evolving and sometimes unstable behaviors.
• Aligning global teams around a shared vision: balance centralized governance with regional needs to ensure coherence, compliance, and local efficiency.
• Securing and stabilizing the generative AI solution: maintain reliability and performance in a fast-changing technological environment.
• Building a clear and shared product approach: establish a product culture within a still-maturing environment, aligning teams around common goals and priorities.

• Accelerated time-to-insight: report generation accelerated by 4–5x and autonomous access to personalized analyses through natural language queries.
  
• Enhanced clinical and strategic decision quality: faster validation or invalidation of hypotheses through quantitative data and improved integration of patient criteria aligned with regulatory expectations.
  
• Strengthened reliability and product maturity: significant reduction in debugging time, improved communication with users, and the emergence of a strong product culture around AI.